GUIDED THERAPEUTICS INC Form 8-K
August 29, 2011
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event) August 29, 2011; August 25, 2011

GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

<u>Delaware</u>	0-22179	<u>58-2029543</u>	
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)	
5835 Peachtree Corners East, Suite D 30092			
Norcross, Georgia	o Code)		
(Address of Principal Executive Offices)			
Registrant's Telephone Number, Including Area Code: (770) 242-8723			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions :			
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

Section 7.01 (Regulation FD Disclosure)

On August 25, 2011, the registrant publicly issued a press release announcing it was awarded \$517,000 to fund the third year of a \$2.5 million, three-year grant from the National Cancer Institute, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

The following exhibit is furnished with this report:

Exhibit No. Description

Press Release

99.1 dated August

25, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GUIDED THERAPEUTICS, INC

By: <u>/s/ MARK L. FAUPEL</u>
Mark L. Faupel, Ph.D.
CEO & President

Date: August 29, 2011